Defiance Daily Target 2X Long LMND ETF (LMNX) Price, Holdings, & News

ETF Overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Key Stats

• Today's Range: $17.28 to $18.79
• 50-Day Range: $36.66 to $37.01
• 52-Week Range: $20.61 to $41.69
• Volume: 13,203 shs
• Average Volume: 873,093 shs
• Market Capitalization: $836.51 million
• Assets Under Management: $884.50 thousand
• Dividend Yield: 2.26%
• Net Expense Ratio: 1.31%
• Aggregate Rating: N/A

LMNX ETF - Frequently Asked Questions

How were Defiance Daily Target 2X Long LMND ETF's earnings last quarter?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) issued its earnings results on Sunday, February, 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.13 by $0.12. The firm's revenue was up 23.1% on a year-over-year basis.

What other stocks do shareholders of Defiance Daily Target 2X Long LMND ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Defiance Daily Target 2X Long LMND ETF investors own include Bristol Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), Cisco Systems (CSCO), NVIDIA (NVDA), Pfizer (PFE) and QUALCOMM (QCOM).

Fund Details

• Issuer: Defiance ETFs
• Fund Name: Defiance Daily Target 2X Long LMND ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NASDAQ
• Current Symbol: NASDAQ:LMNX
• Inception Date: 10/15/2025
• Fund Manager: Stephen Foy
• Web: www.luminexcorp.com
• Phone: 512-219-8020

Fund Focus

• Asset Class: Equity
• Benchmark: N/A
• Category: Strategy
• Focus: Single Stock
• Development Level: Developed Markets
• Region: North America
• Number of Holdings: 5

Fund Statistics

• Assets Under Management: $884.50 thousand
• Average Daily Volume: $0.00
• Discount/Premium: -0.01%
• Leveraged: 2.00

Administrator, Advisor and Custodian

• Administrator: Tidal ETF Services, LLC
• Advisor: Tidal Investments, LLC
• Custodian: U.S. Bank, N.A.
• Distributor: Foreside Fund Services, LLC
• Transfer Agent: U.S. Bancorp Fund Services, LLC
• Trustee: N/A
• Lead Market Maker: N/A

Miscellaneous

• Outstanding Shares: 47,314,000
• Beta: 0.56
• Creation Fee: $300.00